GBT is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
We are developing our initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease, or SCD, and are currently enrolling patients in our pivotal trial program called the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study. More »
In addition to GBT440 for the treatment of SCD, we are evaluating GBT440 as a potential treatment for hypoxemia (low levels of oxygen in the blood). Specifically, we have three ongoing studies including two Phase 2a clinical trials in idiopathic pulmonary fibrosis, or IPF, patients and a Phase 1 study evaluating the effect of GBT440 on oxygen saturation in healthy volunteers. More »